Skip to main content
. 2014 Jul 31;16:419. doi: 10.1186/s13058-014-0419-5

Table 1.

Chronological summary of US Food and Drug Administration approved anti-HER2 treatments in HER2-amplified breast cancer

Year of approval Cancer stage Agent Study name Chemotherapy
1998 [2] First-line metastatic T - Pac or AC
1998 [2] Second-line and third-line metastatic T - None
2006 [1],[15] Adjuvant T B31/N9831/BCIG006 AC → Pac, TCH
2006 [16] Metastatic L - Capecitabine
2009 [17] Metastatic L + AI TAnDEM None
2012 [18] Metastatic P + T CLEOPATRA Docetaxel
2013 [13] Metastatic TDM-1 EMILIA None
2013 [19] Neoadjuvant P + T NeoSphere FEC → Pac, TCH

AI, aromatase inhibitor; AC, doxorubicin and cyclophosphamide; FEC, fluorouracil, epirubicin, cyclophosphamide, HER, human epidermal growth factor receptor; L, lapatinib; P, pertuzumab; Pac, paclitaxel; T, trastuzumab; TCH, docetaxel, carboplatin and trastuzumab; TDM-1, ado-trastuzumab emtansine.